Details for New Drug Application (NDA): 203480
✉ Email this page to a colleague
NDA 203480 describes COLESEVELAM HYDROCHLORIDE, which is a drug marketed by Alkem Labs Ltd, Glenmark Pharms Ltd, Impax, Watson Labs Inc, Beijing Tide Pharm, Bionpharma, Chartwell Rx, Dr Reddys, Impax Labs Inc, Invagen Pharms, Inventia, United Res Labs, Zhejiang Jingxin, and Zydus Pharms, and is included in seventeen NDAs. It is available from fourteen suppliers. Additional details are available on the COLESEVELAM HYDROCHLORIDE profile page.
The generic ingredient in COLESEVELAM HYDROCHLORIDE is colesevelam hydrochloride. There are ten drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the colesevelam hydrochloride profile page.
The generic ingredient in COLESEVELAM HYDROCHLORIDE is colesevelam hydrochloride. There are ten drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the colesevelam hydrochloride profile page.
Summary for 203480
| Tradename: | COLESEVELAM HYDROCHLORIDE |
| Applicant: | Glenmark Pharms Ltd |
| Ingredient: | colesevelam hydrochloride |
| Patents: | 0 |
Pharmacology for NDA: 203480
| Mechanism of Action | Bile-acid Binding Activity |
Medical Subject Heading (MeSH) Categories for 203480
Suppliers and Packaging for NDA: 203480
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| COLESEVELAM HYDROCHLORIDE | colesevelam hydrochloride | TABLET;ORAL | 203480 | ANDA | Glenmark Pharmaceuticals Inc., USA | 68462-433 | 68462-433-18 | 180 TABLET, FILM COATED in 1 BOTTLE (68462-433-18) |
| COLESEVELAM HYDROCHLORIDE | colesevelam hydrochloride | TABLET;ORAL | 203480 | ANDA | Glenmark Pharmaceuticals Inc., USA | 68462-433 | 68462-433-90 | 90 TABLET, FILM COATED in 1 BOTTLE (68462-433-90) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 625MG | ||||
| Approval Date: | May 18, 2018 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
